Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial

Meletios Dimopoulos • 9 Jun 2016
EHA 2016
Multiple Myeloma Antibodies Daratumumab
POLLUX

Press brief by Meletios Dimopoulos, MD of the University of Athens, Athens, Greece, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

More from Meletios Dimopoulos

1:07
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
0:49
KdD vs Kd for R/R MM: renal subgroup analysis from CANDOR
Meletios Dimopoulos • 10 Dec 2023
1:19
Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
1:34
iNNOVATE study update: long-term PFS in WM
Meletios Dimopoulos • 5 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals